Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Temozolomide Plus Metformin in Recurrent or Refractory Glioblastoma
NCT03243851Phase 2Completed
- Start
- Nov 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Temozolomide+metformin with Temozolomide+placebo (2 arms). Primary endpoint: Progression-Free Survival at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
metformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03243851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243851.